A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

About half (53%) of Americans say they hear or read about Ozempic, Wegovy and similar drugs extremely or very often.

Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in ...

The pill version of Wegovy seems to work just as well as the injectable form, but there are some key differences between the ...

A recent scientific study published in the Oman Medical Journal revealed a significant increase in emergency department ...

ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term ...

FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how the next generation of “small ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

A 6-month tailored weight loss program helps US veterans with serious mental illness achieve significant weight reduction.

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered ...